Kymera Therapeutics enters $500M at-the-market offering agreement with TD Cowen

Kymera Therapeutics, Inc.

Agreement allows Kymera to sell up to $500M of common stock through TD Cowen at its discretion.
TD Cowen will receive up to 3.0% commission on gross proceeds from sales under the agreement.
Kymera terminated its prior Open Market Sale Agreement with Jefferies LLC effective February 26, 2026.
Kymera filed a resale prospectus for up to 18,819,826 shares and 12,565,253 warrant shares held by certain stockholders.
The resale filing does not guarantee any sales and Kymera will not receive proceeds from resales by stockholders.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Kymera Therapeutics, Inc. entered into TD Cowen Sales Agreement with TD Securities (USA) LLC valued at up to $500,000,000 (effective 2026-02-26).

Action: entry
Agreement: atm program
Counterparty: TD Securities (USA) LLC
Value: up to $500,000,000
Effective: 2026-02-26

Exact text from the filing

On February 26, 2026, Kymera Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “TD Cowen Sales Agreement”), with TD Securities (USA) LLC (“TD Cowen”) with respect to an “at-the-market” offering program under which the Company may issue and sell, from time to time at the Company’s sole discretion, shares of the Company’s common stock, having an aggregate offering price of up to $500,000,000 (the “Shares”), through TD Cowen.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Kymera Therapeutics, Inc. terminated Open Market Sale Agreement SM with Jefferies LLC (effective 2026-02-26).

Action: termination
Agreement: atm program
Counterparty: Jefferies LLC
Effective: 2026-02-26

Exact text from the filing

On February 26, 2026, Jefferies LLC (“Jefferies”) acknowledged and accepted the Company’s prior written notice to terminate the Open Market Sale Agreement SM , dated as of October 31, 2024, by and between the Company and Jefferies, effective immediately.

View on SEC.gov

311 material agreements filed in the last 30 days. Browse all material agreements →

Kymera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-073561

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.